IUPAC/Chemical Name
((R)-2-((S)-2-((4-carbamimidoylbenzyl)carbamoyl)azetidin-1-yl)-1-cyclohexyl-2-oxoethyl)glycine
InChi Key
DKWNMCUOEDMMIN-PKOBYXMFSA-N
InChi Code
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
SMILES Code
O=C(N(CC1)[C@@H]1C(NCC2=CC=C(C(N)=N)C=C2)=O)[C@@H](C3CCCCC3)NCC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
429.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Belliard A, Mauco G, Bonnet ML, Hauet T, Macchi L. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes. Cell Mol Biol (Noisy-le-grand). 2008 Dec 31;54 Suppl:OL1077-82. PubMed PMID: 19149969.
2: Hellstern P, Stürzebecher U, Wuchold B, Haubelt H, Seyfert UT, Bauer M, Vogt A, Stürzebecher J. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost. 2007 Oct;5(10):2119-26. Epub 2007 Jul 31. PubMed PMID: 17666019.
3: Nitescu N, Grimberg E, Ricksten SE, Marcussen N, Guron G. Thrombin inhibition
with melagatran does not attenuate renal ischaemia-reperfusion injury in rats. Nephrol Dial Transplant. 2007 Aug;22(8):2149-55. Epub 2007 Apr 3. PubMed PMID: 17405786.
4: Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther. 2005 Apr;77(4):279-90. PubMed PMID: 15903126.
5: Fenyvesi T, Jörg I, Weiss C, Harenberg J. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors. Blood Coagul Fibrinolysis. 2004 Oct;15(7):605-11. PubMed PMID: 15389129.
6: Hemdahl AL, Falk E, Thorén P, Hansson GK. Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H872-7. Epub 2004 Mar 18. PubMed PMID: 15031124.
7: Wåhlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res. 2002 Aug 15;107(3-4):93-9. PubMed PMID: 12431473.
8: Fenyvesi T, Joerg I, Harenberg J. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Clin Chem. 2002 Oct;48(10):1791-4. PubMed PMID: 12324500.
9: Fenyvesi T, Jörg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost. 2002 Aug;28(4):361-8. PubMed PMID: 12244483.
